Recent News

By Category: Public Health

FDA Offers First License to Drug Produced by Bioshield Program

(Global Security Newswire) The U.S. Food and Drug Administration on Friday issued a license for a new anthrax treatment, marking the first time the agency has approved a drug developed through the federal government’s controversial Project Bioshield program. The U.S. Health and Human Services Department has since 2005 acquired an unspecified amount of Raxibacumab through  Read More »

Experts to Vet Proposed U.S. Rules on Bird Flu Studies

(Global Security Newswire) An Obama administration proposal to conduct special evaluations of federal grant requests for weapon-sensitive avian influenza research is set to go under the microscope this week at a gathering of public health officials and experts from around the world. The two-day event — scheduled to begin on Monday at the main campus  Read More »

New report signals slowdown in the fight against malaria

(WHO news) During the past decade, a concerted effort by endemic countries, donors and global malaria partners led to strengthened malaria control around the world. The scale-up of malaria prevention and control interventions had the greatest impact in countries with high malaria transmission; 58% of the 1.1 million lives saved during this period were in  Read More »

How Ebola sneaks past immune system

(Futurity) Ebola virus is the causative agent of Ebola Hemorrhagic Fever (EHF), a disease with up to 90 percent mortality. While human outbreaks of Ebola hemorrhagic fever have been confined to Africa, Ebola virus infections in bats, the presumed natural reservoir of the virus, have also been detected in Europe and Asia. Ebola virus infection  Read More »

FDA approves raxibacumab to treat inhalational anthrax

(FDA) The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. Raxibacumab is a monoclonal antibody that  Read More »